Physician profile

Meredith Ann Kriss

Infectious Disease · Phoenix, AZ

NPI 1538804810

$368.38

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$248.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Paratek Pharmaceuticals, INC. $124.58 2022-2023 Nuzyra
Abbvie INC. $72.31 2022-2023
Merck Sharp & Dohme LLC $67.73 2022-2023 Zerbaxa, Dificid, Delstrigo
Viiv Healthcare Company $36.04 2023 Dovato, Apretude
Takeda Pharmaceuticals U.S.A., INC. $32.52 2023 Livtencity
Shionogi INC $17.79 2023 Fetroja
Insmed, INC. $17.41 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Meredith Ann Kriss

$368.38

in general payments reported 2019-2025

Years
2022-2023
Top company
Paratek Pharmaceuticals, INC.

https://glasscript.com/doctor/11319421/meredith-ann-kriss

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.